新型冠状病毒肺炎患者肺移植术中联合应用外周静脉-静脉体外膜氧合与中心静脉-动脉体外膜氧合
南京医科大学附属无锡市人民医院2020年3月收治2例COVID-19终末期呼吸衰竭患者,常规治疗无法维持内环境与生命体征平衡,遂行肺移植。术中见重度肺动脉高压和心功能不全,在术前VV-ECMO基础上加用中心静脉-动脉ECMO(CVA-ECMO)。联合应用提供了满意的术中氧合与心肺状态,手术顺利,CVA-ECMO成功撤除,未发生ECMO相关并发症。作者认为,对合并重度肺动脉高压和心功能不全的终末期ARDS患者,VV-ECMO与CVA-ECMO联合应用是优化策略,可同时改善呼吸与心脏功能、保障手术安全。
要点
- 2例COVID-19终末期呼吸衰竭患者中,例1机械通气22天、气管切开17天、VV-ECMO支持7天;例2分别为19天、17天、18天。
- 两例术中均发现重度肺动脉高压和心功能不全,在术前VV-ECMO基础上加用CVA-ECMO。
- 外周VV-ECMO与CVA-ECMO联合应用提供满意术中氧合与心肺状态,手术顺利,CVA-ECMO成功撤除。
- 未发生ECMO相关并发症。
- 作者认为,合并重度肺动脉高压和心功能不全的终末期ARDS患者,VV-ECMO与CVA-ECMO联合应用是优化策略。
适用人群与场景
- 2例COVID-19终末期呼吸衰竭患者,2020年3月收治于南京医科大学附属无锡市人民医院,常规治疗无法维持内环境与生命体征平衡。
- 例1:59岁,身高172 cm,体重72 kg,机械通气22天,气管切开管17天,VV-ECMO支持7天。
- 例2:72岁,身高178 cm,体重71 kg,机械通气19天,气管切开管17天,VV-ECMO支持18天。
处置流程与药物剂量
- 两例均在术前VV-ECMO支持基础上,术中因发现重度肺动脉高压和心功能不全而加用CVA-ECMO。
- 外周VV-ECMO与CVA-ECMO联合应用,提供满意术中氧合与心肺状态。
- 手术顺利,CVA-ECMO成功撤除,未发生ECMO相关并发症。
研究设计与关键结果
- 2例COVID-19终末期呼吸衰竭患者行肺移植,术中见重度肺动脉高压和心功能不全,在术前VV-ECMO基础上加用CVA-ECMO,联合应用提供满意术中氧合与心肺状态,手术顺利,CVA-ECMO成功撤除,无ECMO相关并发症。
证据类型、等级与局限
- 证据类型:病例报告(2例)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对合并重度肺动脉高压和心功能不全的终末期ARDS患者,VV-ECMO与CVA-ECMO联合应用是优化策略,可同时改善呼吸与心脏功能并保障手术安全。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To summarize the strategy of using extracorporeal membrane oxygenation (ECMO) support during lung transplantation from 2 coronavirus disease 2019 (COVID-19) with end-stage respiratory failure.
METHODS: Two COVID-19 with end-stage respiratory failure patients were admitted to Nanjing Medical University Affiliated Wuxi People's Hospital in March 2020. As the homoeostasis and vital signs could not be maintained in balance by conventional treatments, lung transplantations were performed. Here, detail information about combined application of peripheral veno-venous ECMO (VV-ECMO) and central veno-arterial ECMO (CVA-ECMO) during the operation will be discussed.
RESULTS: Case 1: 59 years old, 172 cm height, 72 kg weight, who received mechanical ventilation for 22 days, tracheotomy tube for 17 days, and VV-ECMO support for 7 days. Case 2: 72 years old, 178 cm height, 71 kg weight, who received mechanical ventilation for 19 days, tracheotomy tube for 17 days, and VV-ECMO support for 18 days. As both of them have severe COVID-19-associated respiratory failure, and the recovery was determined to be unlikely, lung transplantations were performed. Severe pulmonary arterial hypertension (PAH) and cardiac insufficiency were found during the operation. Based on preoperative VV-ECMO, CVA-ECMO was added. The concomitant use of peripheral VV-ECMO and CVA-ECMO offered satisfied intraoperative oxygenation and cardiopulmonary status,the operations run smoothly, and the CVA-ECMO was successfully removed, no ECMO-related complications occurred.
CONCLUSIONS: The combined use of VV-ECMO and CVA-ECMO is an optimal strategy in the end-stage ARDS patients with severe PAH and cardiac insufficiency, which can offer benefits on respiratory and cardiac functions simultaneously, and ensure surgery safety.
参考来源
- Jiao G, Jiang S, Cheng J, et al. [Concomitant use of peripheral veno-venous extracorporeal membrane oxygenation (VV-ECMO) and central veno-arterial ECMO during lung transplantation for coronavirus disease 2019 patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 35131020. doi:10.3760/cma.j.cn121430-20210130-00181
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。